Company intelligence / Profile preview

Abdera Therapeutics

South San Francisco, California, United Statesabderatx.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 1

Overview

Abdera Therapeutics has initiated a Phase 1 clinical trial for its lead program ABD‑147, a DLL3-targeting radiopharmaceutical using Actinium‑225 to treat SCLC and LCNEC. The company also has preclinical data on its second program, ABD‑320 targeting the antigen 5T4. No efficacy or safety results from human trials have been published yet as of May 2025.

Therapeutic areas: Oncology
Modalities: Radiopharmaceuticals (radiotherapeutics)Antibody-based biologics
Industry: Biotech

Drug pipeline

7 assets

ABD-147

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Abdera Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abdera Therapeutics.

Explore the full profile